A new portable blood testing device developed by King's College London spinout Algocyte uses artificial intelligence to analyze blood samples at home and share results instantly with doctors via smartphone app, potentially transforming how patients receive ongoing health monitoring. The device, called PROXIMA Mobile Health Station, connects via Bluetooth and employs AI algorithms to detect subtle changes in a patient's health over time, rather than providing only a single snapshot like traditional laboratory tests.

How Does At-Home AI Blood Testing Work?

The technology operates through a straightforward process that minimizes the burden on patients. Users collect small blood samples using minimally invasive methods such as finger pricking and place them into the portable device. Instead of sending samples to a laboratory for analysis, built-in sensors measure properties of the blood sample directly. Artificial intelligence algorithms then process these measurements to generate blood test results that can be shared digitally with healthcare providers and patients immediately.

This represents a significant shift from traditional blood testing workflows. Most conventional blood tests provide only a snapshot of a person's health at a single moment in time. The PROXIMA system, by contrast, helps identify small changes in an individual's health over time by enabling regular monitoring from home. This capability is particularly valuable for patients who require frequent blood work monitoring as part of their treatment regimen.

Which Patients Could Benefit Most from This Technology?

The technology addresses a critical need for patients undergoing treatments that require close health monitoring. Several patient populations stand to benefit significantly from at-home AI blood testing:

• Chemotherapy Patients: Those receiving cancer treatment currently rely on frequent hospital or GP visits for blood tests to monitor treatment response and side effects.
• Patients on Clozapine: Individuals taking this psychiatric medication require regular blood cell monitoring due to potential serious side effects and complications.
• Patients on Medications Requiring Monitoring: Anyone taking medicines that necessitate close tracking of blood parameters to ensure safety and efficacy.

"This technology could have a real-world impact on the many patients receiving treatments that would benefit from regular blood monitoring, such as chemotherapy or the use of medicines like clozapine, which require close monitoring of blood cell levels due to potential side effects or complications," said Dr. Hector Zenil, founder and CEO of Algocyte and Associate Professor in Healthcare Engineering at King's College London.

Dr. Hector Zenil, Founder and CEO of Algocyte, Associate Professor in Healthcare Engineering at King's College London

The device achieved UKCA regulatory marking, meaning it complies with all relevant health, safety, and environmental protection standards in the United Kingdom. The PROXIMA Mobile Health Station was officially launched at an event at the Royal Society of Medicine in London on June 29, 2026, bringing together researchers, clinicians, industry partners and healthcare leaders to discuss the technology's future development and potential applications.

What Are the Broader Implications for Healthcare Systems?

Beyond individual patient benefits, this technology could significantly reduce strain on healthcare infrastructure. The National Health Service (NHS) in the United Kingdom carries out millions of blood tests annually, with these tests helping doctors diagnose disease, monitor treatments, and assess overall health. By enabling patients to conduct blood analysis at home, the technology could free up substantial resources currently devoted to processing and analyzing blood samples in centralized laboratories.

The development of PROXIMA exemplifies how interdisciplinary collaboration between academia and industry can translate fundamental research into scalable healthcare solutions. Algocyte brought together expertise in artificial intelligence, bioengineering, computational biology, and clinical medicine to address a genuine healthcare challenge. This approach reflects a broader trend in healthcare technology where academic institutions partner with commercial enterprises to move promising innovations from research settings into real-world clinical practice.

Algocyte is continuing to gather scientific evidence and complete further regulatory steps as it works toward making the technology available more widely in different settings and for predictive purposes. The company's progress demonstrates how portable AI-powered diagnostics are beginning to shift healthcare delivery from centralized hospital and laboratory settings toward distributed, patient-centered models where monitoring and early detection can occur in patients' homes.

This development aligns with a broader movement in healthcare toward precision medicine and personalized monitoring. Rather than relying on periodic check-ups and laboratory visits, patients and their healthcare providers can now access continuous or frequent health data that reveals trends and subtle changes over time. For conditions requiring close monitoring, this capability could enable earlier intervention and more responsive treatment adjustments, ultimately improving patient outcomes while reducing the burden of frequent hospital visits.